[Angiotensin converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in microalbuminuric patients with one or more cardiovascular risk factors. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes randomized trial (LIRICO).].
Maione, A
[Angiotensin converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in microalbuminuric patients with one or more cardiovascular risk factors. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes randomized trial (LIRICO).]. [electronic resource] - Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia - 446-56 p. digital
Publication Type: Journal Article; Randomized Controlled Trial
1724-5990
Angiotensin II Type 1 Receptor Blockers--therapeutic use
Angiotensin Receptor Antagonists--therapeutic use
Angiotensin-Converting Enzyme Inhibitors--therapeutic use
Cardiovascular Diseases
Humans
Prospective Studies
Risk Factors
[Angiotensin converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in microalbuminuric patients with one or more cardiovascular risk factors. Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes randomized trial (LIRICO).]. [electronic resource] - Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia - 446-56 p. digital
Publication Type: Journal Article; Randomized Controlled Trial
1724-5990
Angiotensin II Type 1 Receptor Blockers--therapeutic use
Angiotensin Receptor Antagonists--therapeutic use
Angiotensin-Converting Enzyme Inhibitors--therapeutic use
Cardiovascular Diseases
Humans
Prospective Studies
Risk Factors